Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 1/20 | 0.35 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | MGAM | O43451 | 2/20 | 0.32 |
| ▸ | TREH | O43280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23603330 | 0.85 | LGALS3 (0.37) | LGALS3LGALS8OGASLC6A2SPHK1 | |
| SCHEMBL27207966 | 0.85 | LGALS3 (0.37) | LGALS3LGALS8OGASLC6A2SPHK1 | |
| SCHEMBL22423210 | 0.85 | LGALS3 (0.37) | LGALS3LGALS8OGASLC6A2SPHK1 | |
| SCHEMBL23603158 | 0.85 | LGALS3 (0.37) | LGALS3LGALS8OGASLC6A2SPHK1 | |
| SCHEMBL8719944 | 0.85 | LGALS3 (0.37) | LGALS3LGALS8OGASLC6A2SPHK1 | |
| SCHEMBL15246976 | 0.82 | SLC6A2 (0.34) | LGALS3SLC6A2GAAMGAM | |
| SCHEMBL8718887 | 0.80 | LGALS3 (0.36) | LGALS3LGALS8OGASLC6A2SPHK1 | |
| SCHEMBL139795 | 0.80 | LGALS3 (0.36) | LGALS3LGALS8OGASLC6A2SPHK1 | |
| SCHEMBL25421866 | 0.80 | SLC6A2 (0.39) | LGALS3LGALS8OGASLC6A2SPHK1 | |
| SCHEMBL12347313 | 0.80 | SLC6A2 (0.39) | LGALS3LGALS8OGASLC6A2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295629-A1 | ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS | UNIVERSITY OF MASSACHUSETTS | 2023-09-21 | — | — | US | disclosed |
| US-20230041016-A1 | ANTI-SLC6A1 OLIGONUCLEOTIDES AND RELATED METHODS | UNIVERSITY OF MASSACHUSETTS | 2023-02-09 | — | — | US | disclosed |
| US-20230022489-A1 | IDENTIFYING NON-PRODUCTIVE SPLICE SITES | UNIVERSITY OF MASSACHUSETTS | 2023-01-26 | — | — | US | disclosed |
| US-20220403393-A1 | Modulation of Angiopoietin-Like 3 Expression | IONIS PHARMACEUTICALS, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-11225664-B2 | Modulation of angiopoietin-like 3 expression | IONIS PHARMACEUTICALS, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20210285002-A1 | OLIGONUCLEOTIDES TARGETING FRATAXIN AND RELATED METHODS | UNIVERSITY OF MASSACHUSETTS | 2021-09-16 | — | — | US | disclosed |
| US-20210277401-A1 | Compositions and Methods for Modulating PKK Expression | IONIS PHARMACEUTICALS, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210236534-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EXPANDED REPEAT-ASSOCIATED DISORDERS | UNIVERSITY OF MASSACHUSETTS | 2021-08-05 | — | — | US | disclosed |
| US-20210214725-A1 | COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT | IONIS PHARMACEUTICALS, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-10968453-B2 | Compositions for modulating SOD-1 expression | BIOGEN MA INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190249177-A1 | MODULATION OF HUNTINGTIN EXPRESSION | GENZYME CORPORATION | 2019-08-15 | — | — | US | disclosed |
| US-20190231808-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EXPANDED REPEAT-ASSOCIATED DISORDERS | UNIVERSITY OF MASSACHUSETTS | 2019-08-01 | — | — | US | disclosed |
| US-20190002885-A1 | ANTI-ADAM33 OLIGONUCLEOTIDES AND RELATED METHODS | UNIVERSITY OF SOUTHAMPTON (GB) | 2019-01-03 | — | — | US | disclosed |
| US-20180023077-A1 | COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT | IONIS PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20170349897-A1 | COMPOSITIONS FOR MODULATING C9ORF72 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170335329-A1 | ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF | EXCALIARD PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170327527-A1 | METHOD FOR SOLUTION PHASE DETRITYLATION OF OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| US-9765338-B2 | Modulation of dystrophia myotonica-protein kinase (DMPK) expression | IONIS PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| WO-2010042281-A2 | ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF | EXCALIARD PHARMACEUTICALS (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010027830-A2 | METHODS FOR MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION BY ADMINISTERING ANTISENSE OLIGONUCLEOTIDES THROUGH A DELIVERY SYSTEM SO AS TO REDUCE SCARRING FROM WOUND HEALING AND THREAT FIBROTIC DISEASES | EXCALIARD PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277401-A1 | Compositions and Methods for Modulating PKK Expression | GCKR, PKM, PKLR | LGALS3 3380/4885LGALS8 2854/4885OGA 1175/4885 |
| US-20210214725-A1 | COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT | UPF1, RNGTT, RNMT | LGALS3 4305/4885LGALS8 4023/4885OGA 2856/4885 |
| US-20230022489-A1 | IDENTIFYING NON-PRODUCTIVE SPLICE SITES | ATP2A2, CDR2, RBM22 | LGALS3 4825/4885LGALS8 3700/4885OGA 3070/4885 |
| US-20210236534-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EXPANDED REPEAT-ASSOCIATED DISORDERS | PABPC4, PABPC1, RNMT | LGALS3 4229/4885LGALS8 3832/4885OGA 1797/4885 |
| US-20190231808-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EXPANDED REPEAT-ASSOCIATED DISORDERS | PABPC4, PABPC1, RNMT | LGALS3 4229/4885LGALS8 3832/4885OGA 1797/4885 |
| US-20180023077-A1 | COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT | UPF1, RNGTT, RNMT | LGALS3 4305/4885LGALS8 4023/4885OGA 2856/4885 |
| US-20170327527-A1 | METHOD FOR SOLUTION PHASE DETRITYLATION OF OLIGOMERIC COMPOUNDS | TERT, BPHL, DKC1 | LGALS3 596/4885LGALS8 204/4885OGA 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.